Adjunctive nutrients in first-episode psychosis: A systematic review of efficacy, tolerability and neurobiological mechanisms

Early Intervention in Psychiatry

Volumn 12, Issue 5, 2018, Pages 774-783

  Firth, Joseph ^a,b   Rosenbaum, Simon ^c,d   Ward, Philip B ^c,e   Curtis, Jackie ^c,f   Teasdale, Scott B ^c,f   Yung, Alison R ^b,g   Sarris, Jerome ^a,h  

^a WESTERN SYDNEY UNIVERSITY   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^f SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^g GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

amino acids; antioxidants; diet; early psychosis; nutrition; omega 3

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; GLUTATHIONE; OMEGA 3 FATTY ACID; TAURINE;

ADVERSE OUTCOME; BRAIN LEVEL; CLINICAL OUTCOME; DIET SUPPLEMENTATION; FEASIBILITY STUDY; GLUTATHIONE METABOLISM; HIPPOCAMPUS; HUMAN; META ANALYSIS; NEUROBIOLOGY; NUTRITIONAL TOLERANCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; THERAPY EFFECT; COMBINATION DRUG THERAPY; DIET THERAPY; DIETARY SUPPLEMENT; PROCEDURES;

DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; HUMANS; NUTRIENTS; PSYCHOTIC DISORDERS;

EID: 85044185055     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12544     Document Type: Review

References (58)

1. Amminger, G. P., Harris, M. S., McGorry, P. D., & Henry, L. P. (2013). Omega-3 fatty acids for indicated prevention: Treatment results and pathomechanisms. European Archives of Psychiatry and Clinical Neuroscience, 1, S44–S45
2. Amminger, G. P., Schäfer, M. R., Schlögelhofer, M., Klier, C. M., & McGorry, P. D. (2015). Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nature Communications, 6, 7934
3. Berger, G. E., Proffitt, T. M., McConchie, M., Yuen, H., Wood, S. J., Amminger, G. P., … McGorry, P. D. (2007). Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 68, 1867–1875
4. Berger, G. E., Wood, S. J., Wellard, R. M., Proffitt, T. M., McConchie, M., Amminger, G. P., … McGorry, P. D. (2008). Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology, 33, 2467–2473
5. Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., … Bush, A. I. (2008). N-acetyl cysteine as a glutathione precursor for schizophrenia – A double-blind, randomized, placebo-controlled trial. Biological Psychiatry, 64, 361–368
6. Bos, D. J., van Montfort, S. J., Oranje, B., Durston, S., & Smeets, P. A. (2016). Effects of omega-3 polyunsaturated fatty acids on human brain morphology and function: What is the evidence? European Neuropsychopharmacology, 26, 546–561
7. Chaudhry, I. B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson, P., … Deakin, B. (2012). Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. Journal of Psychopharmacology, 26, 1185–1193
8. Conus, P., Seidman, L. J., Fournier, M., Xin, L., Cleusix, M., Baumann, P. S., … Do, K. Q. (2017). N-acetylcysteine in a double-blind randomized placebo-controlled trial: Toward biomarker-guided treatment in early psychosis. Schizophrenia Bulletin, 44, 317–327
9. Dakhale, G. N., Khanzode, S. D., Khanzode, S. S., & Saoji, A. (2005). Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology, 182, 494–498
10. Dean, O. M., Turner, A., Malhi, G. S., Ng, C., Cotton, S. M., Dodd, S., … Berk, M. (2015). Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Revista Brasileira de Psiquiatria, 37, 03–12
11. Devaraj, S., Wang-Polagruto, J., Polagruto, J., Keen, C. L., & Jialal, I. (2008). High-fat, energy-dense, fast-food–style breakfast results in an increase in oxidative stress in metabolic syndrome. Metabolism, 57, 867–870
12. Dipasquale, S., Pariante, C. M., Dazzan, P., Aguglia, E., McGuire, P., & Mondelli, V. (2013). The dietary pattern of patients with schizophrenia: A systematic review. Journal of Psychiatric Research, 47, 197–207
13. Emsley, R., Chiliza, B., Asmal, L., du Plessis, S., Phahladira, L., van Niekerk, E., … Harvey, B. H. (2014). A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophrenia Research, 158, 230–235
14. Eranti, V. S., Gangadhar, B. N., & Janakiramaiah, N. (1998). Haloperidol-induced extrapyramidal reaction: Lack of protective effect by vitamin E. Psychopharmacology, 140, 418–420
15. Farokhnia, M., Azarkolah, A., Adinehfar, F., Khodaie-Ardakani, M.-R., Yekehtaz, H., Tabrizi, M., Akhondzadeh, S. (2013). N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study. Clinical Neuropharmacology, 36, 185–192
16. Firth, J., Carney, R., Stubbs, B., Teasdale, S., Vancampfort, D., Ward, P., … Sarris, J. (2017). Nutritional deficiencies and clinical correlates in first-episode psychosis: A systematic review and meta-analysis. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbx162
17. Firth, J., Stubbs, B., Sarris, J., Rosenbaum, S., Teasdale, S., Berk, M., & Yung, A. (2017). The effects of vitamin and mineral supplementation on symptoms of schizophrenia: A systematic review and meta-analysis. Psychological Medicine, 47, 1515–1527
18. Flatow, J., Buckley, P., & Miller, B. J. (2013). Meta-analysis of oxidative stress in schizophrenia. Biological Psychiatry, 74, 400–409
19. Fotuhi, M., Mohassel, P., & Yaffe, K. (2009). Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: A complex association. Nature Clinical Practice Neurology, 5, 140–152
20. Fusar-Poli, P., & Berger, G. (2012). Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology, 32, 179–185
21. Goff, D. C., Bottiglieri, T., Arning, E., Shih, V., Freudenreich, O., Evins, A. E., … Coyle, J. (2004). Folate, homocysteine, and negative symptoms in schizophrenia. American Journal of Psychiatry, 161, 1705–1708
22. Graham, K. A., Keefe, R. S., Lieberman, J. A., Calikoglu, A. S., Lansing, K. M., & Perkins, D. O. (2015). Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Intervention in Psychiatry, 9, 397–405
23. Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the" right stuff"? Schizophrenia Bulletin, 26, 119–136
24. Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, d5928
25. Ingole, S., Belorkar, N., Waradkar, P., & Shrivastava, M. (2011). Role of ascorbic acid supplementation on prevention of olanzapine induced metabolic side effects in schizophrenic patients. Indian Journal of Public Health Research & Development, 2, 12–16
26. Jääskeläinen, E., Juola, P., Hirvonen, N., McGrath, J. J., Saha, S., Isohanni, M., … Miettunen, J. (2012). A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin, 39, 1296–1306
27. Jacka, F. N., O'Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., … Berk, M. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES'trial). BMC Medicine, 15, 23
28. 12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatry Research, 175, 47–53
29. Kaplan, B. J., Rucklidge, J. J., Romijn, A. R., & Dolph, M. (2015). A randomised trial of nutrient supplements to minimise psychological stress after a natural disaster. Psychiatry Research, 228, 373–379
30. Lundman, P., Boquist, S., Samnegård, A., Bennermo, M., Held, C., Ericsson, C.-G., … Tornvall, P. (2007). A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutrition, Metabolism, and Cardiovascular Diseases, 17, 195–202
31. Malla, A., Norman, R., Schmitz, N., Manchanda, R., BÉChard-Evans, L., Takhar, J., & Haricharan, R. (2006). Predictors of rate and time to remission in first-episode psychosis: A two-year outcome study. Psychological Medicine, 36, 649–658
32. McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schafer, M. R., Mossaheb, N., et al. (2017). Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: The NEURAPRO randomized clinical trial. JAMA Psychiatry, 74, 19–27
33. McGrath, J., Eyles, D., Mowry, B., Yolken, R., & Buka, S. (2003). Low maternal vitamin D as a risk factor for schizophrenia: A pilot study using banked sera. Schizophrenia Research, 63, 73–78
34. McGrath, J., Saari, K., Hakko, H., Jokelainen, J., Jones, P., Järvelin, M.-R., … Isohanni, M. (2004). Vitamin D supplementation during the first year of life and risk of schizophrenia: A Finnish birth cohort study. Schizophrenia Research, 67, 237–245
35. Meyer, U., Schwarz, M. J., & Müller, N. (2011). Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacology & Therapeutics, 132, 96–110
36. Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biological Psychiatry, 70, 663–671
37. Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of Internal Medicine, 151, 264–269
38. Mondelli, V., Cattaneo, A., Murri, M. B., Di Forti, M., Handley, R., Hepgul, N., et al. (2011). Stress and inflammation reduce BDNF expression in first-episode psychosis: A pathway to smaller hippocampal volume. The Journal of Clinical Psychiatry, 72, 1677–1684
39. O'Donnell, C. P., Allott, K. A., Murphy, B. P., Yuen, H. P., Proffitt, T.-M., Papas, A., et al. (2016). Adjunctive Taurine in first-episode psychosis: A phase 2, double-blind, randomized, placebo-controlled study. The Journal of Clinical Psychiatry, 77, e1610–e1617
40. Oulhaj, A., Jernerén, F., Refsum, H., Smith, A. D., & de Jager, C. A. (2016). Omega-3 fatty acid status enhances the prevention of cognitive decline by B vitamins in mild cognitive impairment. Journal of Alzheimer's Disease, 50, 547–557
41. Patrick, R. P., & Ames, B. N. (2015). Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. The FASEB Journal, 29, 2207–2222
42. Pawelczyk, T., Grancow-Grabka, M., Kotlicka-Antczak, M., Trafalska, E., & Pawelczyk, A. (2016). A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. Journal of Psychiatric Research, 73, 34–44
43. Pawelczyk, T., Grancow-Grabka, M., Trafalska, E., Szemraj, J., & Pawelczyk, A. (2017). Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 121, 7–13
44. Rapaport, M. H., Nierenberg, A. A., Schettler, P. J., Kinkead, B., Cardoos, A., Walker, R., & Mischoulon, D. (2016). Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: A proof-of-concept study. Molecular Psychiatry, 21, 71–79
45. Robinson, D. G., Woerner, M. G., McMeniman, M., Mendelowitz, A., & Bilder, R. M. (2004). Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 161(3), 473–479
46. Roffman, J., Petruzzi, L., Tanner, A., Brown, H., Eryilmaz, H., Ho, N., et al. (2017). Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: A randomized controlled trial. Molecular Psychiatry, 23, 316–322
47. Rucklidge, J. J., Johnstone, J., & Kaplan, B. J. (2013). Magic bullet thinking-why do we continue to perpetuate this fallacy? The British Journal of Psychiatry, 203, 154–154
48. Sarris, J., Logan, A. C., Akbaraly, T. N., Amminger, G. P., Balanzá-Martínez, V., Freeman, M. P., … International Society for Nutritional Psychiatry Research. (2015). Nutritional medicine as mainstream in psychiatry. The Lancet. Psychiatry, 2, 271–274
49. Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., & Ng, C. H. (2016). Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. American Journal of Psychiatry, 173, 575–587
50. Sarris, J., Stough, C., Bousman, C., Murphy, J., Savage, K., Smith, D. J., … Mischoulon, D. (2015). An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. Advances in Integrative Medicine, 2, 49–55
51. Shivakumar, V., Kalmady, S. V., Amaresha, A. C., Jose, D., Narayanaswamy, J. C., Agarwal, S. M., … Gangadhar, B. N. (2015). Serum vitamin D and hippocampal gray matter volume in schizophrenia. Psychiatry Research: Neuroimaging, 233, 175–179
52. Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., … Correll, C. U. (2017). Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectrums, 22, 415–426
53. Sommer, I. E., van Westrhenen, R., Begemann, M. J., de Witte, L. D., Leucht, S., & Kahn, R. S. (2013). Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update. Schizophrenia Bulletin, 40(1), 181–191
54. Song, X., Fan, X., Li, X., Kennedy, D., Pang, L., Quan, M., … Lv, L. (2014). Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naive, first episode schizophrenia. Schizophrenia Research, 159, 51–55
55. Teasdale, S. B., Ward, P. B., Rosenbaum, S., Samaras, K., & Stubbs, B. (2016). Solving a weighty problem: Systematic review and meta-analysis of nutrition interventions in severe mental illness. The British Journal of Psychiatry, 210(2), 110–118
56. Teasdale, S. B., Ward, P. B., Rosenbaum, S., Watkins, A., Curtis, J., Kalucy, M., & Samaras, K. (2016). A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis. British Journal of Nutrition, 115, 1987–1993
57. Wood, S. J., Cocchi, L., Proffitt, T. M., McConchie, M., Jackson, G. D., Takahashi, T., … Berger, G. E. (2010). Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study. Psychiatry Research: Neuroimaging, 182, 180–182
58. Yee, J. Y., See, Y. M., Abdul Rashid, N. A., Neelamekam, S., & Lee, J. (2016). Association between serum levels of bioavailable vitamin D and negative symptoms in first-episode psychosis. Psychiatry Research, 243, 390–394